image
Healthcare - Biotechnology - NASDAQ - US
$ 12.36
7.47 %
$ 1.7 B
Market Cap
-2.35
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ARWR stock under the worst case scenario is HIDDEN Compared to the current market price of 12.4 USD, Arrowhead Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ARWR stock under the base case scenario is HIDDEN Compared to the current market price of 12.4 USD, Arrowhead Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one ARWR stock under the best case scenario is HIDDEN Compared to the current market price of 12.4 USD, Arrowhead Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ARWR

image
$28.0$28.0$26.0$26.0$24.0$24.0$22.0$22.0$20.0$20.0$18.0$18.0$16.0$16.0$14.0$14.0$12.0$12.0$10.0$10.0$8.0$8.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
3.55 M REVENUE
-98.52%
-601 M OPERATING INCOME
-193.21%
-610 M NET INCOME
-191.34%
-463 M OPERATING CASH FLOW
-200.77%
-420 M INVESTING CASH FLOW
-336.87%
871 M FINANCING CASH FLOW
244.01%
2.5 M REVENUE
0.00%
-161 M OPERATING INCOME
0.49%
-175 M NET INCOME
-1.08%
-146 M OPERATING CASH FLOW
-6.60%
76.9 M INVESTING CASH FLOW
134.50%
20.6 M FINANCING CASH FLOW
-94.70%
Balance Sheet Arrowhead Pharmaceuticals, Inc.
image
Current Assets 695 M
Cash & Short-Term Investments 681 M
Receivables 0
Other Current Assets 14.5 M
Non-Current Assets 444 M
Long-Term Investments 0
PP&E 431 M
Other Non-Current Assets 13 M
59.74 %37.84 %Total Assets$1.1b
Current Liabilities 103 M
Accounts Payable 11.4 M
Short-Term Debt 6.34 M
Other Current Liabilities 85.4 M
Non-Current Liabilities 846 M
Long-Term Debt 504 M
Other Non-Current Liabilities 341 M
9.01 %53.15 %35.98 %Total Liabilities$948.7m
EFFICIENCY
Earnings Waterfall Arrowhead Pharmaceuticals, Inc.
image
Revenue 3.55 M
Cost Of Revenue 0
Gross Profit 3.55 M
Operating Expenses 605 M
Operating Income -601 M
Other Expenses 8.61 M
Net Income -610 M
100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)(600m)(600m)(700m)(700m)4m04m(605m)(601m)(9m)(610m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-16927.06% OPERATING MARGIN
-16927.06%
-16882.37% NET MARGIN
-16882.37%
-323.27% ROE
-323.27%
-52.60% ROA
-52.60%
-57.37% ROIC
-57.37%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Arrowhead Pharmaceuticals, Inc.
image
200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)(400m)(400m)(500m)(500m)(600m)(600m)(700m)(700m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -610 M
Depreciation & Amortization 18.6 M
Capital Expenditures -141 M
Stock-Based Compensation 74 M
Change in Working Capital 25.1 M
Others 59.8 M
Free Cash Flow -604 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Arrowhead Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for ARWR of $42 , with forecasts ranging from a low of $24 to a high of $60 .
ARWR Lowest Price Target Wall Street Target
24 USD 94.17%
ARWR Average Price Target Wall Street Target
42 USD 239.81%
ARWR Highest Price Target Wall Street Target
60 USD 385.44%
Price
Max Price Target
Min Price Target
Average Price Target
60605050404030302020101000Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Arrowhead Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
7.58 M USD 1
3-6 MONTHS
3.87 M USD 8
6-9 MONTHS
0 USD 0
9-12 MONTHS
279 K USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. “Ken has been a valuable member of the Arrowhea. businesswire.com - 2 weeks ago
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on April 3, 2025, the Company's Board of Directors approved “inducement” grants to 21 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 34,190 restricted stock units. The grants are outside the Company's stockholder-approved equity incentive plans and vest. businesswire.com - 4 weeks ago
Arrowhead Pharmaceuticals Is Finally Arriving Arrowhead Pharmaceuticals, Inc. has streamlined its focus, now boasting 19 clinical programs, including 4 phase 3 trials and 4 phase 2 trials. Plozasiran shows superior results in triglyceride reduction and dosing frequency compared to its main competitor, Olezarsen, with a pivotal PDUFA date on November 18. ARWR's strong financial position is bolstered by a recent deal with Sarepta, extending its cash runway into 2028. seekingalpha.com - 1 month ago
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company's investigational RNA interference (RNAi) therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. The company plans to present additional results at a medical meeting in 2025. Select Phase 1/2 Study Results Patients with IgA nephrop. businesswire.com - 1 month ago
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of two first-in-class clinical stage, RNAi-based investigational therapeutics being developed for the treatment of obesity and metabolic diseases. The two candidates, ARO-INHBE and ARO-ALK7, have the potential to reduce body weight and fat mass with a novel mechanism of action that may lead to improved preservation of lean muscle mass comp. businesswire.com - 1 month ago
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) marks Rare Disease Day with the expansion of the We'll Get There Soon campaign, initially launched for healthcare providers in November 2024. This new phase introduces a dedicated educational website, www.LowerMyTGs.com, and the Spotlight on FCS white paper, which provides essential resources and support for those affected by Familial Chylomicronemia Syndrome (FCS). FCS is an ultra-rare genetic disorder that signi. businesswire.com - 2 months ago
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like kinase 7 (ALK7) being developed as a potential treatment for obesity. The results were presented in a poster at the Keystone Symposia on Obesity and Adipose Tissue held February 23–26, 2025 in Banff, AB, Canada. ARO-ALK7 is the first RNAi-based therapy to directly targe. businesswire.com - 2 months ago
Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions Arrowhead Pharmaceuticals is executing on the clinical and regulatory side during adverse market conditions for biotech companies and genetic stocks in particular. Zodasiran is back in the clinic with a phase 3 trial plan in homozygous familiar hypercholesterolemia patients. We could see as many as three phase 1/2 readouts this year from programs that were recently partnered with Sarepta, and ARO-DM1 program milestones point to registrational intent. seekingalpha.com - 2 months ago
Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Company Participants Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis - SVP & Head of Global Cardio/Metabolic Franchise James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - CFO Conference Call Participants Luca Issi - RBC Capital David Lebowitz - Citi Jasmine Fels - UBS Maury Raycroft - Jefferies Edward Tenthoff - PSC Patrick Trucchio - H.C. Wainwright Mayank Mamtani - B. seekingalpha.com - 2 months ago
Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is hosting a conference call today, February 10, 2025, at 4:30 p.m. ET to discuss the results. “During the recent period, Arrowhead signed and closed a potentially transformational licensing and collaboration agreement with Sarepta Therapeutics and submitted our first NDA for investigational plozasiran, which w. businesswire.com - 2 months ago
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRPT) announced on November 26, 2024, has now closed. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions. Summary Financial Terms Upon closing, Arrowhead receives a $500 milli. businesswire.com - 2 months ago
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 first quarter ended December 31, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approxim. businesswire.com - 3 months ago
8. Profile Summary

Arrowhead Pharmaceuticals, Inc. ARWR

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 1.7 B
Dividend Yield 0.00%
Description Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Contact 177 East Colorado Boulevard, Pasadena, CA, 91105 https://arrowheadpharma.com
IPO Date Dec. 16, 1993
Employees 609
Officers Dr. James C. Hamilton M.D., MBA Chief Medical Officer and Head of R&D Dr. Vincent Anzalone CFA Head of Investor Relations & Vice President Mr. Andy Davis M.B.A. SVice President of Cardiovascular & Head of Metabolic Franchise Mr. Patrick O'Brien J.D., PharmD Chief Operating Officer, General Counsel & Secretary Dr. Bruce D. Given M.D. Chief Medical Scientist Aaron Tan Head of Tax Dr. Mark M. Davis Ph.D. Founder and Founder & Director of Insert Therapeutics Inc & Calando Dr. Mark Seefeld Head of Toxicology & Vice President Mr. Howard Lovy Director of Communications Dr. Christopher R. Anzalone Ph.D. Chairman, Chief Executive Officer & President